Acute Otitis Media Trials: Evolution of Guidance Janice Soreth, M.D. Division of Anti-Infective Drug Products January 30, 2001.

Slides:

Advertisements

Similar presentations

CQ Deng, PhD PPD Development Research Triangle Park, NC 27560

Advertisements

Antimicrobial Prescribing in the Management of COPD

ISTC Training Modules 2008 Your name Institution/organization Meeting Date.

Otitis Media Lawrence Pike.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Community Acquired Pneumonia Guidelines 2011 Top 11 Recommendations Michael H. Kim.

World Health Organization TB Case Definitions

Antimicrobial Resistance in N. gonorrhoeae: In Brief 2014 INTRODUCTION Increased action is needed to help prevent and control gonorrhea. Worldwide antimicrobial.

Augmentin® ES Clinical Microbiology Review

Microbiologic Surrogate Endpoints in Clinical Trials-IDSA FDA/IDSA/ISAP Workshop April 15, 2004 Sheldon L. Kaplan, MD Baylor College of Medicine Texas.

Should we change the recommendations related to antibiotic drug dosage/drug duration? Workshop on Economic Epidemiology Makerere University August, 2009.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

1 Catheter-Related Bloodstream Infection Guidance Revisited Janice Pohlman, M.D. FDA AIDAC Presentation October 14, 2004.

Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.

Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media

1 FDA Trial Design Requirements for CABP David M. Shlaes MD, PhD Anti-infectives Consulting, LLC Stonington, CT.

IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.

Design of Clinical Trials of Antibiotic Therapy for Acute Otitis Media

1 FDA Trial Design Requirements for HABP/VABP David M. Shlaes MD, PhD Anti-infectives Consulting, LLC Stonington, CT.

Acute Bacterial Rhinosinusitis. Brief Background Typically follows viral infection Dx is by clinical manifestations Streptococcus pneumoniae, Haemophilus.

1 Data from Studies in One Indication Supporting Studies in a Different Indication March 5, 2003 Anti Infective Drugs Advisory Committee Meeting Edward.

Bacteremia and CRBSI as Labeled BSI Indications: A Regulatory History Alfred Sorbello, DO Medical Officer CDER/Division of Anti-Infective Drug Products.

Concept Sheet Development: Developing the Question Kara Wools-Kaloustian M.D. M.S.

Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

1 Acute Otitis Media. 2 Acute Otitis Media Clinical Evidence. Neill O, et al. Search date Jan 2006 Acute otitis media (AOM) is a common condition for.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

Otitis/2002/Dagan R. Dagan The Pediatric Infectious Disease Unit Soroka University Medical Center Ben-Gurion University Beer-Sheva, Israel Beer-Sheva,

FinOM Efficacy Trial of 7-Valent Pneumococcal Conjugate Vaccine Terhi Kilpi National Public Health Institute (KTL) Finland.

Giebink – FDA – 07/11/02 Design Issues in Antimicrobial Treatment Trials of AOM G. Scott Giebink, M.D. Professor of Pediatrics and Otolaryngology Director,

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.

1 Exploring Alternative Antibiotic Treatment Regimens: Methodology and Implications Dr. Tabish Hazir MASCOT Study Group 2 nd ICIUM Conference 2004.

1 Otitis Media Results from the Kaiser Permanente Efficacy Trial Steven Black, MD, Henry Shinefield, MD and Bruce Fireman, MS Kaiser Permanente Vaccine.

How Clinicians Use Data For Clinical Decision Making March 5, 2003 Anti-Infective Drug Advisory Committee How Clinicians Use Data For Clinical Decision.

Vaccines and Related Biological Products Advisory Committee (VRBPAC) May 21, 2002 Prevnar™, Pneumococcal Conjugate Vaccine 7-valent, for the Prevention.

Center for Drug Evaluation and Research Anti-Infective Drug Advisory Committee March 6, New Drug Application NDA /S-008 Cubicin® (daptomycin.

Acute Otitis Media To treat or not to treat Gary Kroukamp.

1 PHOTOFRIN® PDT for High-grade Dysplasia in Barrett’s Esophagus Edvardas Kaminskas, M.D. Medical Officer, CDER, ODE III, DGCDP Milton Fan, Ph.D. Statistical.

Question 1 Pozen estimated an annual incidence of tardive dyskinesia (TD) of up to 0.038% for metoclopramide at a daily dose of mg/day for 72 days/year.

1 Observations from Past Approvals for Acute Bacterial Sinusitis Janice Pohlman, M.D. AIDAC Meeting, October 29, 2003.

Issues in development for an MDR TB indication Leonard Sacks MD Division of special pathogens and transplant products FDA.

Indiaclen Short course of Amoxicillin in treatment of Pneumonia (ISCAP) 3 versus 5 days amoxicillin for treatment of non-severe pneumonia in young children:

1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,

Clinical Trials of Acute Otitis Media John Alexander, M.D., M.P.H. Anti-Infective Drugs Advisory Committee November 7, 2001.

Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.

Clinical Practice Guideline in OME Otolaryngol Head Neck Surg May;130(5 Suppl):S

Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.

Catheter-Related Blood Stream Infections A Phase 2 Randomized, Controlled Trial of Dalbavancin vs. Vancomycin Tim Henkel, MD, PhD Executive VP and Chief.

In the Best Interests of the Public Health... Janice Soreth, M.D. Acting Director Division of Anti-Infective Drug Products CDER/FDA.

1 Antibiotic Resistance: An Update Janice Soreth, M.D. Director Division of Anti-Infective Drug Products February 20, 2002.

1 Recent Advances in Provision of Primary Care in the Public Sector: Is 3 Days of Oral Antibiotic Therapy Enough for Treatment of Ambulatory Pneumonia?

Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,

Ketek ™ (Telithromycin) NDA Efficacy Review John Alexander, M.D., M.P.H. Medical Team Leader Division of Anti-Infective Drug Products.

Three days vs five days oral cotrimoxazole therapy in non-severe pneumonia Kartasasmita C, Samir K. Saha * and Cotrimoxazole Study Group Indonesia and.

Study Designs for Acute Otitis Media: What can each design tell us? C. George Rochester, Ph.D. Anti-Infective Advisory Committee Meeting, July 11, 2002.

1 Zithromax  (Azithromycin) Oral Suspension Single-Dose & 3-day Treatment of Acute Otitis Media Anti-Infective Drugs Advisory Committee November 7, 2001.

CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.

Diamantis P. Kofteridis, Christina Alexopoulou, Antonios Valachis, Sofia Maraki, Dimitra Dimopoulou Clinical Infectious Diseases 2010; 51(11):1238–1244.

Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,

1 Issues in Conduct of Catheter Related Infection (CRI) Studies Charles Knirsch, MD, MPH FDA Anti-infective Advisory Committee Meeting October 14, 2004.

Presented by Carl Norden, M.D. at the Anti-Infective Drugs Advisory Committee meeting on October 28, 2003.

Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;

P. Marchisio, S. Esposito, M.Picca, E. Baggi,

Addition of Inhaled Tobramycin to Ciprofloxacin for Acute Exacerbations of Pseudomonas aeruginosa Infection in Adult Bronchiectasis* Diana Bilton, MD;

A Better Solution For Cancer Patients With VTE?

S. Skovbjerg, K. Roos, F. Nowrouzian, M. Lindh, S. E. Holm, I

ژورنال كلاب گوارش دكترقويدل دكترروحاني 8/4/96.

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations D. Andes, W.A. Craig Clinical Microbiology.

Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? O.A. Cornely Clinical Microbiology and.

Presentation transcript:

Acute Otitis Media Trials: Evolution of Guidance Janice Soreth, M.D. Division of Anti-Infective Drug Products January 30, 2001

Guidelines for Clinical Evaluation of Anti-Infective Drugs on AOM (1977) number of trials: not addressed case definition: clinical evidence of AOM (“evidence of inflammation of tympanic membrane and middle ear”) tympanocentesis: required in both studies at baseline. Second tap desirable to obtain data on MEF concentrations and promptness of bacteriologic cure. endpoints: both clinical and microbiologic test of cure: not addressed; 4 weeks of follow-up

Guidelines for Clinical Evaluation of Anti-Infective Drugs on AOM (1977) “In the absence of culture of middle ear fluid, no specific claim can be made regarding the effectiveness of any anti-infective drug.”

Points-to-Consider Document on AOM (1992) number of trials: two suggested - “clinical only” study (no tympanocentesis at baseline) to establish equivalence to an approved product - one clinical/microbiologic study with tympanocentesis at baseline case definition: should be rigid tympanocentesis: strongly encouraged in those patients judged to be therapeutic failures endpoints: clinical; clinical and microbiologic test of cure: not specifically addressed

Points-to-Consider Document on AOM (1992) The open micro study should establish acceptable microbial and clinical outcome in at least 25 patients with H. influenzae, in at least 25 patients with S. pneumoniae, and in at least 15 patients with M. catarrhalis.

IDSA/FDA Guidelines on AOM (1992) number of trials: two suggested - a micro study (100 patients) - a comparative clinical trial (tap optional); double-blind case definition: clinical criteria listed tympanocentesis : tap required in those patients who are not clinical successes (failure, relapse, recurrence) endpoints : clinical; clinical and microbiologic test-of-cure: 1-2 weeks after completion of therapy

AOM Evaluability Criteria Advisory Committee Recommendations (1997 & 1998) number of trials: two suggested - a micro study, non-comparative; increase numbers - a comparative clinical trial case definition: tighten, tighten, tighten tympanocentesis : repeat tap at study day 3-5 as critical measure of treatment efficacy; perform tympanocentesis in all failures endpoints : primary efficacy endpoints are clinical cure at TOC and pathogen eradication. test-of-cure: TOC visit 2-4 weeks after study entry. Enhance efforts to enroll patients with penicillin- resistant organisms

AOM Evaluability Criteria Advisory Committee Recommendations (1998) With regard to the microbiologic endpoint: “Tympanocentesis obtained at the on-therapy visit should not be considered evidence of documented eradication. Rather, a negative culture result may represent antimicrobial suppression.”

AOM Evaluability Criteria Advisory Committee Recommendations (1998) Enroll more patients < 2 years of age. Gain much more experience with penicillin- resistant organisms.

“All Comers” v. “Enriched” Trial Increase the number of patients under 24 months of age Enroll patients with ruptured TM’s, history of recurrent otitis, antibiotic prophylaxis Include patients with recent AOM who have failed a course of antibiotics